Three lessons from making 100% in three months
Independent Financial Research
Three lessons from making 100% in three months. Acrux is the patent owner of a testosterone replacement therapy (TRT) called Axiron. When it gained FDA approval in 2010, its share price more than doubled from $1.80 to $4.40 over two years. But in January this year the FDA launched an investigation into the safety of TRT. Acrux's share price crashed back to 75 cents by June. We thought the stock was trading below its intrinsic value and upgraded to a Buy. Sentiment had changed by August, and the stock rocketed back towards $2.00 where we sold half our position. Finally, on September 17 an FDA committee recommended Axiron's labels should include extra risks. Acrux's share price fell nearly 20% in a day and we sold what remained of our position at $1.35, locking in a 110% profit including dividends. Read our top three lessons from the rollercoaster ride: (VIEW LINK)
Intelligent Investor is an independent financial research service with a 14-year history of beating the market. Our value investing approach empowers Australians to make more informed decisions to build their long-term wealth. We off structural...
No areas of expertise